Handelsbanken Fonder AB Purchases 10,400 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Handelsbanken Fonder AB boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 29.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 45,900 shares of the biotechnology company’s stock after buying an additional 10,400 shares during the quarter. Handelsbanken Fonder AB’s holdings in BioCryst Pharmaceuticals were worth $275,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Fifth Third Bancorp raised its stake in shares of BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,500 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 2,388 shares during the last quarter. JGP Global Gestao de Recursos Ltda. acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth $64,000. MA Private Wealth bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $76,000. Finally, Great Valley Advisor Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 34.7% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 4,200 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Down 2.0 %

Shares of NASDAQ BCRX opened at $4.48 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.06. The stock has a market cap of $924.36 million, a price-to-earnings ratio of -3.80 and a beta of 1.96. The company’s fifty day moving average is $4.95 and its 200-day moving average is $5.48.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $89.19 million. On average, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $13.83.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.